Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avutometinib - Verastem Oncology

Next Previous
Drug Profile

Avutometinib - Verastem Oncology

Alternative Names: AVMAPKI FAKZYNJA CO-PACK; AVMAPKI™; CH 5127566; CH-5126766; CKI-27; R-7304; Raf/MEK inhibitor VS-6766; RG 7304; RO-5126766; VS-6766

Latest Information Update: 16 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Amgen; Eli Lilly and Company; Verastem Oncology
  • Class Antineoplastics; Benzopyrans; Ethers; Fluorinated hydrocarbons; Ketones; Pyridines; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Mitogen-activated protein kinase inhibitors; Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase II Colorectal cancer; Gastric cancer; Gynaecological cancer; Non-small cell lung cancer; Thyroid cancer; Uveal melanoma
  • Phase I/II Adenocarcinoma; Glioblastoma; HER2 negative breast cancer; Malignant melanoma; Solid tumours
  • Phase I Multiple myeloma

Most Recent Events

  • 13 Jul 2025 Updated efficacy and adverse events data from the phase-II RAMP 201 trial in Ovarian cancer released by Verastem Oncology
  • 30 Jun 2025 Updated efficacy and adverse events data from the phase I/II FRAME trial in Solid tumours released by Verastem Oncology
  • 30 May 2025 Updated adverse events and efficacy data from the phase-Ib/II RAMP205 trial in Adenocarcinoma presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top